Assessment of peptides to reduce inflammation in acutely burned skin

  • Research type

    Research Study

  • Full title

    An ex-vivo assessment of pro-inflammatory cytokine release from acutely burned skin and ex-vivo assessment of the efficacy of JEL2603 and other peptides at reducing the cytokine release compared to positive and negative controls.

  • IRAS ID

    304771

  • Contact name

    Fadi Issa

  • Contact email

    fadi.issa@nhs.net

  • Sponsor organisation

    Carocell Bio Limited

  • Duration of Study in the UK

    0 years, 2 months, 29 days

  • Research summary

    Severe burn injuries are not only life threatening but can be significantly disfiguring leading to a low quality of life and mental health issues for the survivors. The ultimate aim of this study is to produce a topical peptide that reduces inflammation and scarring in burns victims.

    Having had promising results in the laboratory using new peptides to reduce inflammation, this study hopes to reproduced the results and evaluate the peptides ability to reduce inflammation in acutely burned human skin.
    In order for scientific evaluation of the peptides on acutely burned human skin, this study aims to recruit 2 groups of participants:

    1. participants who have unfortunately sustained significant burn injuries requiring burns excisional surgery - the excised burned skin, which is discarded in standard practice, will be collected and analysed with the new peptides in the laboratory

    2. participants undergoing elective breast reconstruction surgery with DIEP free flap - a small area at the edge of the flap (usually excised and discarded in standard practice) will be burned under controlled conditions, excised and examined with the new peptides in the laboratory.

    The study will be conducted at Stoke Mandeville Hospital, Aylesbury, and the tissue samples will be further analysed in a laboratory in Cheshire.

    This is potentially a ground breaking advance in burns surgery and management as reducing inflammation can reduce fluid loss, accelerate healing and reduce scarring, which can significantly improve the quality of life in patients with severe burns injuries.

  • REC name

    London - London Bridge Research Ethics Committee

  • REC reference

    22/PR/0082

  • Date of REC Opinion

    23 Feb 2022

  • REC opinion

    Further Information Favourable Opinion